EBOS Group Limited (EBOS) notes the announcement by the Australian Competition and Consumer Commission (ACCC) today that it will not oppose the proposed acquisition of LifeHealthcare announced on 9 December 2021.
The transaction remains subject to satisfaction of certain conditions precedent and the parties continue to work diligently towards completion of the transaction, which is expected in FY22.
The ACCC will not oppose the proposed acquisition of Australian Pacific Health Supplies TopCo1 Pty Limited and its subsidiaries (Pacific Health Group) by EBOS Group Limited (ASX: EBO), through its subsidiary EBOS Medical Devices Australia Pty Limited.
EBOS and Pacific Health Group distribute a range of medical devices to private and public hospitals and to clinicians. Pacific Healt h Group also manufactures and distributes allografts through its Australian Biotechnologies business. In general, the majority of the parties’ offerings are complementary and not in direct competition.
A copy of the statement by the ACCC is attached.
Comments from our readers
No comments yet
Add your comment:
Related News:
CEN - Contact Chair to retire this year, new Chair appointed
May 1st Morning Report
GTK - Gentrack's Veovo Acquires Dubai Technology Partners
SML - Additional information following Bright Dairy announcement
April 30th Morning Report
Rua Bioscience Market Update
FSF - Fonterra announces interim leadership changes
April 29th Morning Report
NZK - Blue Endeavour Pilot Farm and Wellboat Update
TRU - FY 31 March 2026 Revenue and Results Guidance Achieved
See IRG research reports
